Zie ook literatuurlijst niet-toxische middelen en behandelingen specifiek bij melanomen van arts-bioloog drs. Engelbert Valstar

Zie ook dit artikel: https://kanker-actueel.nl/chirurgie-pdt-foto-dynamische-therapie-met-bremachlorin-geeft-veel-betere-overall-overleving-op-5-jaar-dan-alleen-chirurgie-van-melanomen-vanuit-moedervlekken-ontstaan.html 

14 november 2021: Zie ook dit artikel: https://kanker-actueel.nl/vrouw-met-een-progressief-stadium-iiib-melanoom-behandeld-met-oncolytisch-echo-7-virus-rigvir-virus-komt-in-totale-remissie-en-is-nu-al-10-jaar-klinisch-kankervrij-na-1e-diagnose.html

4 oktober 2021. Bron: ESMO 2021

Wanneer patiënten waarvan hun melanoom (stadium IIB en IIC bij diagnose)  operatief is weggehaald en na de operatie een jaar lang immuuntherapie met het anti-PD medicijn pembrolizumab krijgen dan vermindert de kans op overlijden en de kans op een recidief geschat met 35 procent in vergelijking met een placebo. Dat stellen de onderzoekers in een presentatie van hun studie na 1-jaars analyse. Dat blijkt uit de eerste resultaten van de fase III Keynote 716 studie gepresenteerd op ESMO 2021. 

Ter vergelijking blijkt uit deze studie dat 100 procent van de patiënten die met PDT - Foto Dynamische Therapie plus bremachlorin werden behandeld hadden geen recidief gerkegen na 5 jaar. En bij totaal 49 patiënten (24 vs 25) bleek op 5 jaar iedereen uit de chirurgie + PDT groep nog te leven versus slechts 9 uit 24 patienten uit de groep die alleen chirurgie kregen

Maar zie verder hier de resultaten van pembrolizumab versus placebo

Uit het abstract vertaald:

In totaal werden 976 melanoompatienten (64% stadium IIB; 34,8% stadium IIC) gerandomiseerd ingedeeld in twee groepen (487 kregen pembrolizumab; 489 patiënten kregen een placebo).

  • Bij een mediane follow-up van 14,4 maanden verlengde pembrolizumab de ziektevrije tijd (RFS) significant versus placebo (HR 0,65, 95% BI 0,46-0,92; P=0,00658; mediaan niet bereikt voor beide groepen).
  • 54 patienten uit de pembrolizumabgroep (11,1%) vs. 82 patienten uit de placebogroep (16,8%) hadden een recidief gekregen met bijna een halvering van het aantal recidieven op afstand in de pembrolizumabgroep (23 patiënten) vs. placebogroep (38 patiënten).
  • Het 12-maanden ziektevrije percentage was 90,5% in de pembrolizumabgroep versus 83,1% in de placebogroep.
  • Graad ≥ 3 ernstige bijwerkingen door welke oorzaak dan ook kwamen voor bij 125 patiënten in de pembrolizumabgroep (25,9%) vs. 83 patiënten in de placebogroep (17,1%).
  • Geneesmiddelgerelateerde bijwerkingen van graad 3 kwamen voor bij 78 patiënten in de pembrolizumabgroep (16,1%) versus 21 patiënten in de placebogroep (4,3%);
  • 74 patiënten uit de pembrolizumabgroep (15,3%) vs 12 patiënten uit de placebogroep (2,5%) stopten vanwege een geneesmiddelgerelateerde ernstige bijwerking. Er traden geen sterfgevallen op als gevolg van een ernstige bijwerking of geneesmiddelgerelateerde bijwerking in de pembrtolizumabgroep; in de placebogroep overleden vier patiënten als gevolg van ernstige bijwerkingen door welke oorzaak dan ook.
  • Immuungemedieerde bijwerkingen kwamen voor bij 36,2% (pembrolizumabgroep) versus 8,4% (placebogroep), meestal hypothyreoïdie (schildklier maakt te weinig hormonen aan) (15,7% versus 3,5%) en hyperthyreoïdie (te snel werkende schildklier) (10,4% versus 0,6%). De meeste waren graad 1-2 van ernst.
Hier het abstract van de studie zoals die op ESMO 2021 werd gepresenteerd. Voor het persbericht van ESMO klik hier.:

LBA3_PR - Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial

Date

18 Sep 2021

Session

Presidential symposium 1

Presenters

Jason Luke

Citation

Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741

Authors

J.J. Luke1, P. Rutkowski2, P. Queirolo3, M. Del Vecchio4, J. Mackiewicz5, V. Chiarion Sileni6, L. de la Cruz Merino7, M.A. Khattak8, D. Schadendorf9, G.V. Long10, P.A. Ascierto11, M. Mandala12, F. De Galitiis13, V. Sondak14, R.A. Scolyer15, J.M. Kirkwood16, K. Chen17, N. Ibrahim17, S. Ahsan17, A.M.M. Eggermont18

Author affiliations

More

Resources

Login to access the resources on OncologyPRO.

Abstract LBA3_PR

Background

Current standard of care for patients (pts) after resection of high-risk stage II melanoma is observation. In the phase 3 double-blind KEYNOTE-716 trial we evaluated pembrolizumab (pembro) versus placebo in pts with resected AJCC-8 stage IIB or IIC melanoma. We present results of the first recurrence-free survival (RFS) interim analysis.

Methods

Eligible pts aged ≥12 years with complete resection of cutaneous stage IIB or IIC melanoma with negative sentinel lymph node biopsy were randomized 1:1 to pembro 200 mg (2 mg/kg for pediatric pts) or placebo Q3W for 17 cycles (up to 1 year). Randomization was stratified by T category 3b, 4a, 4b (adults) with a separate stratum for pediatric pts. Treatment continued until disease recurrence or unacceptable toxicity. The primary endpoint was RFS per investigator assessment. Safety was also evaluated. The data cutoff date for the interim analysis was December 4, 2020.

Results

Overall, 976 pts (64% stage IIB; 34.8% stage IIC) were randomized (487 pembro; 489 placebo). At median follow-up of 14.4 months, pembro significantly prolonged RFS vs placebo (HR 0.65, 95% CI 0.46-0.92; P=0.00658; median not reached for both). 54 (11.1%) vs 82 (16.8%) pts had a recurrence with almost halving of distant recurrence events in the pembro (23) vs placebo (38) group. The 12-month RFS rate was 90.5% vs 83.1%. Grade ≥3 any-cause AEs occurred in 125 (25.9%) vs 83 (17.1%) pts in the pembro vs placebo group. Grade ≥3 drug-related AEs occurred in 78 (16.1%) vs 21 (4.3%) pts; 74 (15.3%) vs 12 (2.5%) discontinued due to a drug-related AE. No deaths due to any-cause AE or drug-related AEs occurred with pembro; four deaths due to any-cause AEs occurred with placebo. Immune-mediated AEs occurred in 36.2% vs 8.4%, most commonly hypothyroidism (15.7% vs 3.5%) and hyperthyroidism (10.4% vs 0.6%). Most were grade 1-2 in severity.

Conclusions

Adjuvant pembrolizumab for resected stage IIB and IIC melanoma decreased the risk of disease recurrence or death by 35% compared with placebo and was associated with significantly prolonged RFS and a favorable benefit-risk profile.

Clinical trial identification

NCT03553836; EudraCT 2018-000669-35; First posted: June 12, 2018.

Editorial acknowledgement

Editoral assistance was provided by Luana Atherly-Henderson, PhD, CMPP an employee of Merck Sharp & Dohme, Corp.

Legal entity responsible for the study

Merck Sharp & Dohme Corp.

Funding

Merck Sharp & Dohme Corp.

Disclosure

J.J. Luke: Financial Interests, Personal, Advisory Board: 7 Hills; Financial Interests, Personal, Advisory Board: Fstar; Financial Interests, Personal, Advisory Board: RefleXion; Financial Interests, Personal, Advisory Board: Alphamab Oncology; Financial Interests, Personal, Advisory Board: Arch Oncology; Financial Interests, Personal, Advisory Board: Kanaph; Financial Interests, Personal, Advisory Board: Onc.AI; Financial Interests, Personal, Advisory Board: Pyxis; Financial Interests, Personal, Advisory Board: Tempest; Financial Interests, Personal, Advisory Board: AbbVie; Financial Interests, Personal, Advisory Board: Alnylam; Financial Interests, Personal, Advisory Board: Array; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Checkmate; Financial Interests, Personal, Advisory Board: Cstone; Financial Interests, Personal, Advisory Board: Eisai; Financial Interests, Personal, Advisory Board: EMD Serono; Financial Interests, Personal, Advisory Board: Flame; Financial Interests, Personal, Advisory Board: Gilead; Financial Interests, Personal, Advisory Board: Kadmon; Financial Interests, Personal, Advisory Board: KSQ; Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Personal, Advisory Board: Immunocore; Financial Interests, Personal, Advisory Board: Inzen; Financial Interests, Personal, Advisory Board: Crown; Financial Interests, Personal, Advisory Board: Macrogenics; Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal, Advisory Board: Mersana; Financial Interests, Personal, Advisory Board: Nektar; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Regeneron; Financial Interests, Personal, Advisory Board: Ribon; Financial Interests, Personal, Advisory Board: Rubius; Financial Interests, Personal, Advisory Board: Silicon; Financial Interests, Personal, Advisory Board: Synlogic; Financial Interests, Personal, Advisory Board: TRex; Financial Interests, Personal, Advisory Board: Werewolf; Financial Interests, Personal, Advisory Board: Xilio; Financial Interests, Personal, Advisory Board: Xencor; Financial Interests, Personal, Ownership Interest: Actym; Financial Interests, Personal, Ownership Interest: Alphamab Oncology; Financial Interests, Personal, Ownership Interest: Arch Oncology; Financial Interests, Personal, Ownership Interest: Kanaph; Financial Interests, Personal, Ownership Interest: Mavu; Financial Interests, Personal, Ownership Interest: Onc.AI; Financial Interests, Personal, Ownership Interest: Pyxis; Financial Interests, Personal, Ownership Interest: Tempest; Financial Interests, Institutional, Invited Speaker: AbbVie; Financial Interests, Institutional, Research Grant: Agios; Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Institutional, Invited Speaker: Astellas; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb; Financial Interests, Institutional, Invited Speaker: Corvus; Financial Interests, Institutional, Invited Speaker: EMD Serono; Financial Interests, Institutional, Invited Speaker: Genmab; Financial Interests, Institutional, Invited Speaker: Ikena; Financial Interests, Institutional, Invited Speaker: Immatics; Financial Interests, Institutional, Invited Speaker: Incyte; Financial Interests, Institutional, Invited Speaker: Kadmon; Financial Interests, Institutional, Invited Speaker: KAHR; Financial Interests, Institutional, Invited Speaker: Macrogenics; Financial Interests, Institutional, Invited Speaker: Merck; Financial Interests, Institutional, Invited Speaker: Moderna; Financial Interests, Institutional, Invited Speaker: Nektar; Financial Interests, Institutional, Invited Speaker: Numab; Financial Interests, Institutional, Invited Speaker: Replimmune; Financial Interests, Institutional, Invited Speaker: Rubius; Financial Interests, Institutional, Invited Speaker: Fstar; Financial Interests, Institutional, Invited Speaker: Synlogic; Financial Interests, Institutional, Invited Speaker: Takeda; Financial Interests, Institutional, Invited Speaker: Trishula; Financial Interests, Institutional, Invited Speaker: Tizona; Financial Interests, Institutional, Invited Speaker: Xencor. P. Rutkowski: Financial Interests, Institutional, Principal Investigator: Merck; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: Pierre Fabre; Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Personal, Invited Speaker: Blueprint Medicines; Financial Interests, Personal, Invited Speaker: Philogen. P. Queirolo: Financial Interests, Advisory Role: Bristol Myers Squibb; Financial Interests, Advisory Role: MSD; Financial Interests, Advisory Role: Merck; Financial Interests, Advisory Role: Novartis; Financial Interests, Advisory Role: Pierre Fabre; Financial Interests, Advisory Role: Sun Pharma; Financial Interests, Advisory Role: Sanofi-Regeneron; Financial Interests, Advisory Role: Roche. M. Del Vecchio: Financial Interests, Institutional, Principal Investigator: Merck; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Advisory Role: Pierre Fabre; Financial Interests, Advisory Role: Sanofi. J. Mackiewicz: Financial Interests, Institutional, Principal Investigator: Merck; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: Pierre Fabre; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: MSD. V. Chiarion Sileni: Financial Interests, Institutional, Principal Investigator: Merck; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Merck-Serono; Financial Interests, Personal, Advisory Role: Pierre-Fabre; Financial Interests, Personal, Other, Travel expenses: BMS; Financial Interests, Personal, Other, Travel expenses: Pierre Fabre. L. de la Cruz Merino: Financial Interests, Institutional, Principal Investigator: Merck; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Institutional, Principal Investigator: Celgene; Financial Interests, Personal, Principal Investigator: Roche; Financial Interests, Personal, Other, Travel expenses: Roche. M.A. Khattak: Financial Interests, Personal, Principal Investigator: Merck. D. Schadendorf: Financial Interests, Institutional, Principal Investigator: Merck; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: Pierre Fabre; Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Personal, Invited Speaker: Merck; Financial Interests, Personal, Invited Speaker: Sandoz; Financial Interests, Personal, Invited Speaker: Philogen; Financial Interests, Personal, Invited Speaker: UltimoVacs; Financial Interests, Personal, Invited Speaker: Neracare; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: 4SC; Financial Interests, Personal, Invited Speaker: InFlarX; Financial Interests, Personal, Invited Speaker: Immunocore; Financial Interests, Personal, Invited Speaker: Nektar; Financial Interests, Personal, Invited Speaker: OncoSec; Financial Interests, Personal, Invited Speaker: Regeneron; Financial Interests, Personal, Invited Speaker: Sun Pharma; Financial Interests, Personal, Invited Speaker: Array; Financial Interests, Personal, Invited Speaker: Replimune; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Pierre Fabre; Financial Interests, Personal, Advisory Role: Sanofi; Financial Interests, Personal, Advisory Role: Merck; Financial Interests, Personal, Advisory Role: Sandoz; Financial Interests, Personal, Advisory Role: Philogen; Financial Interests, Personal, Advisory Role: UltimoVacs; Financial Interests, Personal, Advisory Role: Neracare; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: 4SC; Financial Interests, Personal, Advisory Role: InFlarX; Financial Interests, Personal, Advisory Role: Imunocore; Financial Interests, Personal, Advisory Role: Nektar; Financial Interests, Personal, Advisory Role: OncoSec; Financial Interests, Personal, Advisory Role: Regeneron; Financial Interests, Personal, Advisory Role: SunPharma; Financial Interests, Personal, Advisory Role: Array; Financial Interests, Personal, Advisory Role: Replimmune; Financial Interests, Personal, Speaker’s Bureau: Novartis; Financial Interests, Personal, Speaker’s Bureau: BMS. G.V. Long: Financial Interests, Institutional, Principal Investigator: Merck; Financial Interests, Personal, Advisory Role: Aduro Biotech Inc; Financial Interests, Personal, Advisory Role: Amgen Inc; Financial Interests, Personal, Advisory Role: Array Biopharma Inc; Financial Interests, Personal, Advisory Role: Bristol Myers Squibb; Financial Interests, Personal, Advisory Role: Evaxion Biotech A/S; Financial Interests, Personal, Advisory Role: Hexel AG; Financial Interests, Personal, Advisory Role: Highlight Therapeutics SL; Financial Interests, Personal, Advisory Role: Merck Sharp Dohme; Financial Interests, Personal, Advisory Role: Novartis Pharma AG; Financial Interests, Personal, Advisory Role: OncoSec; Financial Interests, Personal, Advisory Role: Pierre Fabre; Financial Interests, Personal, Advisory Role: QBiotics Group Limited; Financial Interests, Personal, Advisory Role: Regeneron Pharmaceutical Inc; Financial Interests, Personal, Advisory Role: SkylineDX BV; Financial Interests, Personal, Advisory Role: Specialised Therapeutics Australia Pty Ltd. P.A. Ascierto: Financial Interests, Institutional, Principal Investigator: Merck; Financial Interests, Institutional, Principal Investigator: Bristol Myers Squibb; Financial Interests, Institutional, Principal Investigator: Roche-Genentech; Financial Interests, Institutional, Principal Investigator: Array; Financial Interests, Institutional, Principal Investigator: Sanofi; Financial Interests, Personal, Advisory Role: Bristol Myers Squibb; Financial Interests, Personal, Advisory Role: Roche-Genentech; Financial Interests, Personal, Advisory Role: Merck Sharp Dohme; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Merck-Serono; Financial Interests, Personal, Advisory Role: Pierre-Fabre; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: Sun Pharma; Financial Interests, Personal, Advisory Role: Sanofi; Financial Interests, Personal, Advisory Role: Idera; Financial Interests, Personal, Advisory Role: Sandoz; Financial Interests, Personal, Advisory Role: Immunocore; Financial Interests, Personal, Advisory Role: 4SC; Financial Interests, Personal, Advisory Role: Italfarmaco; Financial Interests, Personal, Advisory Role: Nektar; Financial Interests, Personal, Advisory Role: Boehringer-Ingelheim; Financial Interests, Personal, Advisory Role: Eisai; Financial Interests, Personal, Advisory Role: Regeneron; Financial Interests, Personal, Advisory Role: Daiichi Sankyo; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: Oncosec; Financial Interests, Personal, Advisory Role: Nouscom; Financial Interests, Personal, Advisory Role: Lunaphore; Financial Interests, Personal, Advisory Role: Seagen; Financial Interests, Personal, Advisory Role: iTeos. M. Mandala: Financial Interests, Institutional, Principal Investigator: Merck; Financial Interests, Institutional, Principal Investigator: Novartis; Financial Interests, Institutional, Principal Investigator: Roche; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: Pierre Fabre. F. De Galitiis: Financial Interests, Personal, Principal Investigator: Merck. V. Sondak: Financial Interests, Institutional, Principal Investigator: Merck; Financial Interests, Institutional, Principal Investigator: Neogene Therapeutics; Financial Interests, Personal, Advisory Role: Bristol Myers Squibb; Financial Interests, Personal, Advisory Role: Eisai; Financial Interests, Personal, Advisory Role: Merck; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Regeneron; Financial Interests, Personal, Advisory Role: Replimune. R.A. Scolyer: Financial Interests, Institutional, Principal Investigator: Merck; Financial Interests, Personal, Advisory Role: Evaxion; Financial Interests, Personal, Advisory Role: Provectus; Financial Interests, Personal, Advisory Role: Obiotics; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Merck Sharp and Dohme; Financial Interests, Personal, Advisory Role: NeraCare; Financial Interests, Personal, Advisory Role: Amgen Inc; Financial Interests, Personal, Advisory Role: Bristol Myers Squibb; Financial Interests, Personal, Advisory Role: Myriad Genetics; Financial Interests, Personal, Advisory Role: GlaxoSmithKline. J.M. Kirkwood: Financial Interests, Personal, Principal Investigator: Merck. K. Chen: Financial Interests, Personal, Full or part-time Employment: Merck; Financial Interests, Personal, Stocks/Shares: Merck. N. Ibrahim: Financial Interests, Personal, Full or part-time Employment: Merck; Financial Interests, Personal, Stocks/Shares: Merck. S. Ahsan: Financial Interests, Personal, Full or part-time Employment: Merck; Financial Interests, Personal, Stocks/Shares: Merck. A.M.M. Eggermont: Financial Interests, Institutional, Principal Investigator: Merck; Financial Interests, Personal, Invited Speaker: Biocad; Financial Interests, Personal, Advisory Board: BioInvent; Financial Interests, Personal, Advisory Board: BioNTech; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: CYTimmune; Financial Interests, Personal, Advisory Board: Dash Therapeutics; Financial Interests, Personal, Advisory Board: CatalYm; Financial Interests, Personal, Advisory Board: Ellipses; Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Personal, Advisory Board: IO Biotech; Financial Interests, Personal, Advisory Board: ISA Pharmaceuticals; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Nektar; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: RiverD; Financial Interests, Personal, Advisory Board: Sellas; Financial Interests, Personal, Advisory Board: Skyline Dx; Financial Interests, Personal, Advisory Board: TxDiscovery; Financial Interests, Personal, Advisory Board: TigaTx; Financial Interests, Personal, Advisory Role: Biocad; Financial Interests, Personal, Advisory Role: BioInvent; Financial Interests, Personal, Advisory Role: BioNTech; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: CYTimmune; Financial Interests, Personal, Advisory Role: Dash Therapeutics; Financial Interests, Personal, Advisory Role: CatalYm; Financial Interests, Personal, Advisory Role: Ellipses; Financial Interests, Personal, Advisory Role: GSK; Financial Interests, Personal, Advisory Role: IO Biotech; Financial Interests, Personal, Advisory Role: ISA Pharmaceuticals; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Advisory Role: Nektar; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: RiverD; Financial Interests, Personal, Advisory Role: Sellas; Financial Interests, Personal, Advisory Role: Skyline Dx; Financial Interests, Personal, Advisory Role: TxDiscovery; Financial Interests, Personal, Advisory Role: TigaTx; Financial Interests, Personal, Speaker’s Bureau: Biocad; Financial Interests, Personal, Speaker’s Bureau: BMS; Financial Interests, Personal, Speaker’s Bureau: MSD; Financial Interests, Personal, Stocks/Shares: Dash Therpeutics; Financial Interests, Personal, Stocks/Shares: IO Biotech; Financial Interests, Personal, Stocks/Shares: SkylineDx.


Plaats een reactie ...

1 Reactie op "Pembrolizumab gegeven na operatie voor melanoompatienten met stadium IIB en IIC verminderde het risico op overlijden en recidief met 35 procent in vergelijking met een placebo"

  • e.valstar :
    De ziekte komt minder op korte termijn terug, maar of de genezingskans toeneemt of de overlevingsduur toeneemt staat niet vast. De relapsfree survival is beter niet meer dan dat!!!!!!!

Gerelateerde artikelen
 

Gerelateerde artikelen

Tumor-infiltrerende lymfocyten >> Vrouw met een progressief >> Pembrolizumab gegeven na operatie >> Relatlimab plus nivolumab >> Nivolumab plus ipilimumab >> Pembrolizumab geeft betere >> Chronische immuungerelateerde >> Fecale microbiota transplantatie >> Immuuntherapie met nivolumab >> Melanoompatiënten (stadium >>